T. Rowe Price Group, Inc. TROW

The Polish founders of a fast-growing British AI start-up have seen the value of their stakes in the business surge to almost £5bn in a new funding deal.

The $300 million employee tender was co-led by Wellington and T. Rowe Price.

Mutual Fund Report for PRSVX

T. Rowe Price Group has seen its share price move around over the past few years, and the stock now trades at about US$105.51. That puts fresh attention on what investors are really paying for the returns the business earns on its capital. With performance over different timeframes pointing in different directions, the key issue is whether the current market value lines up with the profitability of the asset base that supports those earnings. Over the past 5 years the stock has fallen 33.4%,...

T. Rowe Price recently expanded its exchange traded lineup by launching three fully transparent, actively managed equity ETFs on NASDAQ: a biotech ETF (TDNA, expense ratio 0.55%), a small-cap ETF (TSEE, 0.59%), and a mid-cap equity research ETF (TMID, 0.47%). This push into biotech, small-cap, and mid-cap active ETFs highlights T. Rowe Price’s effort to broaden its product set and reach new types of investors. We’ll now examine how this active ETF expansion, especially the biotech-focused...

Asset manager dividends look safe until a bear market hits and fee revenue collapses with asset prices. The way these two giants earn their money means one of them faces a compounding threat that most income investors are not pricing in.

Mutual Fund Report for PRDMX

Mutual Fund Report for RPGEX

What can investors learn from a global CEO whose career has been shaped by geopolitical disruption, operational crises, and the challenge of making decisions in uncertain markets?

There are a number of things to consider, including the fate of the products investors love, when their issuer is acquired.

Mutual Fund Report for PRGSX

Some lawmakers are questioning whether the majority of demand is coming from investors or the industry.

The competition to win the convergence race is heating up.

Mutual Fund Report for TRLGX

Blue Macellari of asset manager T. Rowe Price said agency rulemaking could replace the CLARITY Act and move faster.